Research Paper Volume 11, Issue 17 pp 6805—6838

Figure 5. HOTAIRM1 silencing inhibits glioma cell proliferation, migration, invasion, and EMT and increases sensitivity to TMZ in vitro. (A) Cell proliferation after transfection of cells with si-HOTAIRM1-1 and -2, as determined with the CCK-8 assay. (B) Migration and invasion in U87 and LN229 cells evaluated with transwell assays. (C) Western blot analysis of E-cadherin (epithelial marker) and vimentin (mesenchymal marker) expression following HOTAIRM1 knockdown; β-actin served as a loading control. (D) Prognostic value of radiochemotherapy compared with radiotherapy alone in high- and low-exp groups. (E) Viability of U87 and LN229 cells transfected with siRNA against HOTAIRM1 (si-HOTAIRM1) or negative control siRNA (si-NC) following TMZ treatment at indicated doses. Values represent mean ± SD (n = 3 biological replicates). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student’s t test).